Loading...
•
Sep 30, 2025
Viatris Q3 2025 Earnings Report
Viatris reported Q3 2025 results with flat revenues and a net loss due to investment value reductions and tax expenses.
Key Takeaways
Viatris posted flat revenue in Q3 2025, with a net loss of $128 million primarily due to a decline in the fair value of Biocon Biologics shares and higher tax expense. Despite this, the company maintained strong adjusted profitability and raised full-year guidance.
Total revenue for Q3 2025 was $3.76 billion, flat compared to the prior year.
Reported net loss of $128 million due to fair value reduction of Biocon Biologics investment and tax increase.
Adjusted EBITDA was $1.15 billion and adjusted EPS was $0.67.
Raised full-year 2025 guidance for revenue, adjusted EBITDA, and adjusted EPS.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Viatris raised and narrowed its 2025 guidance ranges, reflecting FX tailwinds and strong execution. The company now projects revenue between $13.9B and $14.3B, adjusted EBITDA between $4.0B and $4.2B, and adjusted EPS between $2.25 and $2.35.
Positive Outlook
- Raised total revenue guidance to $13.9–$14.3B.
- Increased adjusted EBITDA guidance to $4.0–$4.2B.
- Adjusted EPS guidance raised to $2.25–$2.35.
- Strong share repurchase program supported EPS improvements.
- Positive FX tailwinds contributed to upward revisions.
Challenges Ahead
- Guidance excludes potential impacts from future acquisitions.
- Does not account for further share repurchases post-Nov 5.
- Adjusted metrics exclude transaction-related costs.
- Continued uncertainty from Indore manufacturing impact.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...